CEO Executive AssistantHealth economics and outcomes research has moved from a supporting function to a central pillar of pharmaceutical commercial strategy. In a market where payers, health technology assessment bodies, and formulary committees increasingly make coverage and reimbursement decisions based on comparative effectiveness and cost-effectiveness evidence, the ability to generate, communicate, and deploy HEOR evidence effectively is a direct determinant of commercial success. Pharma CEO health economics coordination is the operational infrastructure that keeps this function aligned with executive priorities: the systems, calendars, meeting structures, and communication protocols that allow the CEO to lead HEOR strategy with clarity while ensuring that the evidence generation and communication apparatus is operating at full capacity. The executive assistant who owns this coordination function is not a health economist, but they are the structural backbone that allows health economics leadership to function without friction.
The Strategic Importance of HEOR in Pharma Leadership
Health economics and outcomes research shapes the commercial trajectory of a pharmaceutical product in ways that are increasingly comparable to clinical development in their impact on market access and revenue. Payers in every major market require HEOR evidence to support formulary decisions. Health technology assessment bodies, including NICE in the United Kingdom, IQWIG in Germany, and the Institute for Clinical and Economic Review (ICER) in the United States, conduct formal cost-effectiveness evaluations that directly influence coverage and pricing in their respective markets.
According to ISPOR, health economics and outcomes research provides the evidence that informs decisions about the value of health interventions across clinical, economic, and patient-centered dimensions. For pharma CEOs, HEOR is not a post-approval compliance exercise; it is a pre-launch strategic investment that determines whether a product’s clinical value translates into commercial access.
The coordination demands of leading HEOR strategy are substantial. Evidence generation requires multi-year planning, external research partnerships, and integration with clinical development timelines. HEOR communication requires coordination across medical affairs, market access, commercial, and external affairs functions. Value dossier development for HTA submissions involves complex cross-functional workflows with hard regulatory deadlines. All of these demands compete for the CEO’s attention alongside investor relations, board management, and organizational leadership. EA-driven pharma CEO health economics coordination is what makes it possible to manage all of these responsibilities without critical gaps.
What Health Economics Coordination Covers
For a pharma CEO’s executive assistant, health economics coordination spans several interconnected domains:
- HEOR evidence generation planning and milestone tracking
- HTA submission timeline management and CEO briefing coordination
- Value dossier development process coordination
- Payer evidence communication meeting preparation
- HEOR advisory board and external expert engagement scheduling
- Real-world evidence study design review meeting coordination
- HEOR publication plan tracking and CEO review coordination
- Budget impact model review session management
- Patient-reported outcome instrument development coordination
- HEOR conference and scientific forum engagement management
Each domain requires proactive calendar management and the organizational discipline to ensure that complex, long-horizon evidence generation processes remain on track against commercial launch and market access timelines.
HEOR Evidence Generation Coordination
Pharmaceutical HEOR evidence generation is a multi-year process that must be planned and initiated long before regulatory submission if the resulting evidence is to be available at the time of payer and HTA review. The EA coordinates the CEO’s engagement with the evidence generation planning process and tracks progress against the integrated evidence plan.
Integrated Evidence Plan Oversight
The integrated evidence plan is the master document that aligns clinical development, real-world evidence generation, and HEOR study design with the evidentiary requirements of key markets and payer segments. The EA coordinates the CEO’s review of the integrated evidence plan at defined intervals, ensuring that plan updates are routed for review with adequate lead time, that cross-functional alignment sessions are scheduled and supported, and that the CEO has the background materials needed to engage substantively with evidence generation strategy decisions.
When gaps or risks in the evidence plan are identified, the EA manages the escalation and resolution process: scheduling the appropriate decision-making forum, ensuring that options and recommendations are presented to the CEO in a format that supports rapid decision-making, and tracking the implementation of decisions through follow-up coordination with the HEOR and clinical functions.
Real-World Evidence Study Coordination
Real-world evidence studies require coordination across research operations, data partnerships, regulatory affairs, and external research organizations. The EA manages the CEO’s periodic engagement with RWE study progress: scheduling quarterly or semi-annual review sessions, ensuring that the CEO receives study progress reports with adequate context for strategic oversight, and coordinating the interface between the HEOR function and investor communications when RWE study results have material commercial implications.
For real-world evidence studies that involve academic medical center partnerships or patient registry collaborations, the EA manages the correspondence and meeting logistics associated with these external relationships at the executive level, ensuring that partner engagement reflects the strategic importance the CEO places on these collaborations.
HTA and Value Dossier Coordination
Health technology assessment submissions are among the most consequential and time-constrained deliverables in pharmaceutical market access. Missed HTA deadlines can delay market entry by months or years in critical markets. Inadequate dossier quality can result in negative coverage recommendations that are difficult to overturn. The EA manages the CEO’s engagement with the HTA submission process with particular precision.
HTA Timeline Architecture
The EA builds and maintains a master HTA submission calendar that maps submission deadlines, pre-submission meeting dates, and coverage decision timelines for every priority market. For a multinational product launch, this calendar may include submissions to NICE (UK), HAS (France), IQWIG/GBA (Germany), CADTH (Canada), PBAC (Australia), and multiple other HTA bodies, each with different submission formats, evidence requirements, and review timelines.
The CEO’s engagement with this calendar is strategic: understanding which submissions carry the greatest commercial risk, which markets require direct executive engagement with HTA bodies or health ministry officials, and which submission timelines are at risk of slippage. The EA ensures that the CEO has current visibility into HTA timeline status and is alerted to risks with adequate lead time for intervention.
Value Dossier Development Process Management
Value dossier development for major HTA submissions is a complex, multi-month cross-functional project. The EA coordinates the CEO’s engagement with this process: scheduling milestone review sessions at key development stages, ensuring that the CEO’s strategic input is incorporated at the appropriate points in the drafting process, and managing the review and approval workflow for executive sign-off on final dossier submissions.
For dossiers that will be submitted to high-scrutiny HTA bodies with track records of critical assessments, the EA coordinates the preparation of the CEO for potential outcomes, including negative recommendations or requests for additional evidence, ensuring that response strategy options are developed in advance rather than reactively.
For coordination frameworks that address the intersection of health economics evidence and medical affairs communication strategy, medical affairs support provides a complementary model for managing the scientific communication infrastructure that supports HEOR evidence deployment.
Payer Evidence Communication Coordination
Generating strong HEOR evidence is necessary but not sufficient for commercial success. Evidence must be communicated effectively to payer decision-makers, formulary committee members, and health system executives through channels and formats that match their decision-making needs. The CEO plays a critical role in senior payer relationships, and the EA coordinates this engagement with precision.
Payer Advisory Board Management
Payer advisory boards are a primary mechanism through which pharma CEOs engage payer thought leaders on evidence requirements, coverage decision criteria, and value framework preferences. The EA manages the full lifecycle of payer advisory board meetings: coordinating with market access leadership to develop the advisory board agenda, managing participant invitations and logistics, ensuring that the CEO has a thorough briefing on each participant’s background and institutional perspective before the meeting, and coordinating the documentation and follow-through on advisory board insights and recommendations.
Advisory board insights should be captured systematically and fed back into the HEOR evidence generation plan and the value communication strategy. The EA manages the process of ensuring this happens: scheduling the post-advisory board synthesis session, coordinating distribution of the advisory board summary to relevant functions, and tracking the incorporation of advisory board recommendations into functional work plans.
Executive Payer Engagement Coordination
For major payer accounts, the CEO may engage directly with Chief Medical Officers, pharmacy directors, or senior coverage decision-makers. The EA manages the scheduling, preparation, and follow-through for these engagements: coordinating with market access leadership on the strategic objective for each engagement, ensuring that the CEO has current coverage status, open contracting issues, and any outstanding evidence requests before the meeting, and managing the documentation and follow-through on any commitments made during the conversation.
For coordination frameworks that connect payer engagement to the broader pricing and contracting strategy, pricing strategy support provides an operational model for managing the CEO’s engagement with pharmaceutical pricing decisions and payer contracting negotiations.
HEOR Publications and Scientific Communication Coordination
HEOR evidence has impact only when it reaches the audiences that need it. The publications plan is the primary vehicle through which HEOR evidence enters the scientific literature and becomes available to payer decision-makers, HTA reviewers, and clinical prescribers. The EA coordinates the CEO’s engagement with the publications plan at a strategic oversight level.
Publications Plan Review Coordination
The EA schedules periodic CEO review of the HEOR publications plan, ensuring that the plan reflects the current evidence generation status and that priority publications are on track to be available ahead of key HTA and payer review timelines. When publication delays or retargeting decisions require executive input, the EA manages the briefing and decision process.
For major HEOR publications with commercial significance, such as a landmark cost-effectiveness analysis or a high-profile real-world evidence study published in a leading health economics journal, the EA coordinates the communication planning around the publication: ensuring that the medical affairs and market access teams have aligned on the deployment strategy, that the CEO is briefed on the publication’s findings and their implications, and that external communication materials are prepared and reviewed before the publication date.
HEOR Conference Engagement Management
ISPOR, HTAi, and other major health economics conferences are important forums for presenting HEOR evidence, engaging payer and HTA thought leaders, and building the organizational reputation as a credible HEOR contributor. The EA manages the CEO’s conference engagement calendar: coordinating abstract submission processes where CEO co-authorship is involved, scheduling conference participation logistics, managing the CEO’s side meeting schedule at conferences where strategic stakeholder engagement opportunities exist, and ensuring that post-conference insights are documented and distributed to relevant internal audiences.
Budget Impact Modeling and Financial Evidence Coordination
Budget impact models are an increasingly important complement to cost-effectiveness analyses in payer decision-making. Payers want to understand not only whether a product is cost-effective in the abstract but what the budget impact of coverage will be for their specific population. The EA coordinates the CEO’s engagement with budget impact model development and deployment.
Model Review and Validation Coordination
When new budget impact models are developed or existing models are updated for new indications or populations, the EA schedules CEO review sessions and ensures that the CEO has appropriate context for evaluating model assumptions and outputs. For models that will be used in high-stakes payer negotiations, the EA coordinates an extended review process that includes input from market access leadership and, where appropriate, external health economics advisors.
Payer-Facing Model Deployment Coordination
Budget impact models that will be presented to payers require preparation that extends beyond the model itself. The EA ensures that the CEO has visibility into the deployment plan, that payer presentations using the model have been reviewed for consistency with the overall market access message, and that the CEO is prepared for payer questions about the model’s methodology and underlying assumptions.
Conclusion
Pharma CEO health economics coordination is a strategically critical operational function that determines whether HEOR evidence is generated on schedule, communicated effectively, and deployed at the moments that matter most for market access and commercial success. From integrated evidence plan oversight and HTA submission timeline management to payer advisory board coordination and publications plan review, every domain of health economics strategy benefits from the consistent, proactive coordination that a skilled EA provides. Organizations that build robust HEOR coordination infrastructure into the CEO support function position themselves to compete effectively in an access environment where evidence quality and communication discipline are the primary determinants of coverage and reimbursement success. For pharma CEOs, this is not a back-office administrative function. It is a front-line competitive capability.